Tiziana Says Experimental MS Treatment Meets Main Goals in Mid-Stage Study
Tiziana Life Sciences said its experimental therapy reduced brain inflammation and showed a favorable safety profile in a mid-stage trial for progressive multiple sclerosis.
Related stories
NAPCO Shares Fall 17.2% After Q1 Revenue Miss
M impact | EQUITY | Nov 02, 2026, 02:43 PM UTC
German Traffic Systems Shares on Track for Worst Day in 25 Years After Outlook Cut
M impact | EQUITY | Nov 02, 2026, 02:43 PM UTC
Kosmos Energy shares fall 13% after Q3 revenue miss
Kosmos Energy shares are down 13% after the company missed revenue expectations for the third quarter.
M impact | EQUITY | Nov 02, 2026, 02:43 PM UTC
Truckers Maintain Strike, Block Container Access at San Antonio Port
Truckers are maintaining a strike and blocking container access at San Antonio ahead of Chile’s peak cherry-export season.
M impact | EQUITY | Nov 02, 2026, 02:43 PM UTC
Twin Disc Maintains Quarterly Dividend at $0.05 per Share
Twin Disc kept its quarterly dividend at $0.05 per share, payable Dec. 1 to holders of record Nov. 18.
M impact | EQUITY | Nov 02, 2026, 02:42 PM UTC
Ryanair CEO Sees European Airfares Rising Up to 20% Next Year
Ryanair’s CEO expects European plane ticket prices may climb as much as 20% next year, with jet fuel prices rising.
L impact | EQUITY | Nov 02, 2026, 02:42 PM UTC